BioSpace News Archive

At Kite, Shaw will focus on turning around the company’s flagship CAR-T treatment Yescarta, as well as focus on the development of other cancer-targeting cell therapies.

Researchers last year identified a gene, mEAK-7, that now appears to play a significant role in how lung cancer metastasizes.

A recent study found that combining a well-known breast cancer drug with a lung cancer drug, at least in cells in the laboratory, was significantly more effective in killing cancer cells.

The companies indicate they hope to continue data analysis to better understand the disease and will present anything relevant at a future scientific meeting.

As the beta-amyloid theory of Alzheimer’s disease fades from prominence, many researchers are turning their attention to the role of inflammation. Although beta-amyloid is still very much a factor in the disease, many believe that it is an uncontrolled or faulty inflammatory and immune reaction to beta-amyloid that causes the majority of the cognitive damage.

David Lickrish took time to speak with BioSpace about the companies’ new drug, Jornay PM (methylphenidate HCL Extended-Release CLL Capsules), and how it fits into the overall ADHD therapeutic market.

Two separate analyses point to difficulties biosimilar manufacturers have had in carving out market share of branded drugs.

The new strategy uses the deactivated Cas13 enzyme to guide RESCUE to targeted cytosine bases on RNA transcripts.

It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), today announced that the Food and Drug Administration (“FDA”) has provided guidance to the Company following its Sprint Discussion on June 26, 2019,